Investigating how SERINC5 blocks HIV-1 infection
The role of SERINC5 in HIV-1 replication
This study is looking at how a protein called SERINC5 helps stop HIV from spreading and why some strains of the virus can get around it, which could help us find better ways to treat and prevent HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10817137 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of SERINC5, a protein that inhibits HIV-1 replication. The study aims to uncover the molecular mechanisms by which SERINC5 prevents the virus from entering cells and how it is counteracted by another viral protein called Nef. By examining different strains of HIV-1, the research will explore why some strains are more resistant to SERINC5 than others. This could lead to new insights into HIV treatment and prevention strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of HIV-1 infection or those living with HIV who may benefit from new treatment approaches.
Not a fit: Patients who are not affected by HIV-1 or those with other unrelated health conditions may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing HIV-1 infection.
How similar studies have performed: Previous research has shown that targeting viral entry mechanisms can be effective in HIV treatment, suggesting potential for success in this approach.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Zheng, Yong-Hui — University of Illinois at Chicago
- Study coordinator: Zheng, Yong-Hui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.